Real-World Data Shows Significant Reduction in Hospital Stay Using AVITA Medical’s RECELL® System

Core Insights - AVITA Medical, Inc. reaffirms that the RECELL® System significantly reduces hospital length of stay (LOS) by an average of 36% compared to traditional split thickness skin grafts (STSG) for adult patients with deep partial thickness burns [1][2][8] - The RECELL System is clinically validated as a cost-effective option in modern burn management, improving patient outcomes and hospital efficiency [2][5] Company Overview - AVITA Medical is a leading therapeutic acute wound care company focused on delivering transformative solutions, with the RECELL System at the forefront [6] - The RECELL System utilizes a patient's own skin to create an autologous skin cell suspension autograft, enhancing recovery at the point of care [2][6] Economic Impact - The use of RECELL is associated with potential per patient cost savings exceeding $42,000, based on an average daily inpatient bed cost of $7,554 [3] - The reduction in LOS allows hospitals to treat 13 more patients per bed annually compared to STSG treatment [3] Clinical Findings - A matched analysis of 741 adults showed that RECELL-treated patients had an average 5.6-day reduction in hospital LOS, representing a 36% decrease compared to STSG [2][8] - In 2023, U.S. burn cases consumed over 110,000 ICU days, costing more than $676 million, highlighting the need for efficient burn care solutions [4] Regulatory Approvals - The RECELL System is approved for various applications in international markets, including thermal burn and trauma wounds, with approvals in Australia, Europe, and Japan [7]